2025Annual Transcatheter Cardiovascular Therapeutics (TCT) The conference was held in San Francisco, where leading global cardiovascular companies showcased breakthrough technological advancements, covering cutting-edge achievements in the treatment of hypertension, heart failure, valvular diseases, and calcified lesions, among others.It's these.Report on Key Technological Breakthroughs:

Medtronic Symplicity Spyral RDN System: A Milestone in Hypertension Treatment

Medtronic AnnouncesSPYRAL HTN-ON MEDLong-term Data of the Trial andSPYRAL AFFIRMPreliminary Results of the High-Risk Cohort Study. The system achieves lasting control of hypertension by ablating renal artery nerves using radiofrequency energy.SPYRAL HTN-ON MEDShow that the blood pressure control rate of patients significantly improved after treatment, while the drug dosage did not increase.；AFFIRMStudies have confirmed that patients with high cardiovascular risk6Blood pressure continued to decrease at months with good safety. The system has been obtained.80Approved by Mr. Guo, and on2023Year11Monthly AcquisitionFDAMilestone Certification, Becoming the World's First Widely Applied Renal Denervation (RDN) Technology.

Johnson & Johnson Medical Technologies Impella CP Heart Pump: A Revolution in Cardiogenic Shock Survival Rates

DanGer ShockTest10Annual follow-up data shows,Impella CPReduce All-Cause Mortality in Patients with Acute Myocardial Infarction Complicated by Cardiogenic Shock16.3%, an average of more survival600Day.As the world's smallest heart pump, this device temporarily replaces the heart's pumping function through minimally invasive intervention, promoting heart recovery. Evidence-driven.ACC/AHAThe guideline update explicitly recommends its use in the treatment of cardiogenic shock patients, becoming the first mechanical circulatory support system to demonstrate long-term survival benefits in randomized controlled trials.

Boston Scientific Agent Drug-Coated Balloon: A New Solution for In-Stent Restenosis

FDAIn2024Year3Approved inAgent DCBPerformed excellently in the research. Based onCathPCIReal-world data coverage in the registry12,000Example patient,Showing its effectiveness in reducing in-stent restenosis;JapanALLIANCEThe registration study further validates its application in complexPCIThe safety in China supports either standalone or combined drug-eluting stent strategies. This technology achieves localized drug release through a paclitaxel coating, avoids permanent implants, and preserves vascular physiological function.

Edwards SAPIEN 3 Ultra RESILIA Valve: A Breakthrough in Long-Term Durability for TAVR

PARTNER 3The seven-year follow-up results of the trial confirmed that transcatheter aortic valve replacement (TAVR) Comparable to surgical outcomes in low-risk patients.TAVRThe seven-year all-cause mortality, stroke, or rehospitalization rate in the group showed no significant difference compared to the surgical group, and the valve hemodynamics were stable, with a lower rate of moderate to severe paravalvular leakage.1%。Research to Address Core Clinical Concerns and ProveTAVRThe long-term safety and durability in low-risk populations are driving its transformation from "high-risk patient selection" to "whole lifecycle management."

Abbott Tendyne Mitral Valve Replacement: A New Treatment Option for MAC Patients

For severe mitral annulus calcification (MAC) Patient,TendyneThe system achieves valve replacement through a minimally invasive transapical approach.SUMMIT-MACThe trial showed that the success rate of the surgery96%，30Day99%Patients Achieve Complete Reflux Elimination, Maintained for Two Years93%No reflux status. This technique is for patients who cannot tolerate traditional open-chest surgery orMitraClipProvide Alternatives for High-Risk Patients with EdwardsSapien M3Form differentiated competition.

FastWave Medical Sola Laser IVL System: Precise Treatment for Calcified Lesions

SolaThe system adopts a single-emitter design, utilizing laser-driven circumferential acoustic pressure waves to safely fragment calcified plaques. The first-in-human trial confirmed its safety in treating complex calcified lesions.30Main adverse cardiac events (MACE) Low rate, surgical success rate meets the standard. This technology optimizes operational control, reduces the risk of vascular injury, and provides a new tool for the treatment of coronary artery calcification.

Recor Medical Paradise Ultrasound RDN System: Dual Giants in Hypertension Treatment

Competing with the Medtronic systemParadiseUltrasoundRDNThe platform also announced positive data.GPSRegistration Research andRADIANCEThe pooled analysis of the trials showed that it is safe and effective in lowering blood pressure, and2023Year11Monthly AcquisitionFDARecognition. The system achieves denervation through ultrasonic energy, forming a competitive technological route with radiofrequency technology and jointly promoting progress.RDNClinical Application of Therapy.

TCT 2025The conference gathers global innovative achievements, ranging from precision treatment of hypertension to minimally invasive interventions for valvular diseases, from improving survival rates of cardiogenic shock to safe management of calcified lesions. Multiple technologies have been validated for safety and efficacy through long-term follow-up data, offering better solutions for cardiovascular disease treatment. These advancements not only demonstrate technological breakthroughs but also signify the progression of cardiovascular disease management towards "full life cycle, personalized, and minimally invasive" approaches.

END

More exciting content

Welcome to follow WeChat Video Channel

Instrument Family

Related Reading

Tap for more!

Limit Up! This Leading Chinese-Made Device Company Undergoes Major Asset Restructuring

China-produced AI Imaging Leader Plans IPO

A Sneak Peek at the CIIE: Medical "Black Tech" Arrives (Part 2)

China's Leading Game Company Enters the Medical Device Industry

The Father of Surgical Robots Invests in Surgical Robots Again

Global Proton Therapy Equipment Leader, Asia-Pacific Headquarters Lands in China

Japanese Device Giant Completes $10.8 Billion Acquisition

Global Leader in Disposable Endoscopes Makes New Moves

119 Units for 269 Million Yuan: Suzhou Launches 2025 Imaging Equipment Centralized Procurement

BusinessBusiness cooperation email: qxzj@landianyiliao.com